Legal & General Group
AGRX

Legal & General Group’s Agile Therapeutics AGRX Stock Holding History

Legal & General Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed -$17K – 3708
2021
Q1 		$17K Hold
4
– – ﹤0.01% 3197
2020
Q4 		$23K Hold
4
– – ﹤0.01% 3047
2020
Q3 		$24K Sell
4
-2
-33% -$11.5K ﹤0.01% 2929
2020
Q2 		$31K Buy
+6
New +$31.2K ﹤0.01% 2885
2017
Q2 		– Sell
-2
Closed -$10K – 3399
2017
Q1 		$10K Hold
2
– – ﹤0.01% 3197
2016
Q4 		$17K Buy
+2
New +$28K ﹤0.01% 3147

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's AGRX Position: Q2 2021 in Review

Legal & General Group sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 4 shares — an estimated $17K sold.

Legal & General Group first reported a position in AGRX in Q4 2016 and held it in 6 quarters. The position peaked at $31K in Q2 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • Legal & General Group reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 4 Agile Therapeutics shares in Q2 2021, an estimated $17K.
  • Legal & General Group first reported a position in Agile Therapeutics in Q4 2016 and held it in 6 quarters.
  • Legal & General Group's Agile Therapeutics position peaked at $31K in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.